CN110730665A - 用2’-岩藻糖基乳糖化合物治疗炎症性肠病 - Google Patents

用2’-岩藻糖基乳糖化合物治疗炎症性肠病 Download PDF

Info

Publication number
CN110730665A
CN110730665A CN201880038002.6A CN201880038002A CN110730665A CN 110730665 A CN110730665 A CN 110730665A CN 201880038002 A CN201880038002 A CN 201880038002A CN 110730665 A CN110730665 A CN 110730665A
Authority
CN
China
Prior art keywords
fucosyllactose
ibd
compound
subject
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880038002.6A
Other languages
English (en)
Chinese (zh)
Inventor
A·L·莫罗
L·A·登森
D·S·纽伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincinnati Childrens Hospital Medical Center
Original Assignee
Cincinnati Childrens Hospital Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincinnati Childrens Hospital Medical Center filed Critical Cincinnati Childrens Hospital Medical Center
Publication of CN110730665A publication Critical patent/CN110730665A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201880038002.6A 2017-04-07 2018-04-07 用2’-岩藻糖基乳糖化合物治疗炎症性肠病 Pending CN110730665A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762482840P 2017-04-07 2017-04-07
US62/482,840 2017-04-07
PCT/US2018/026631 WO2018187792A1 (en) 2017-04-07 2018-04-07 Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds

Publications (1)

Publication Number Publication Date
CN110730665A true CN110730665A (zh) 2020-01-24

Family

ID=63712677

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880038002.6A Pending CN110730665A (zh) 2017-04-07 2018-04-07 用2’-岩藻糖基乳糖化合物治疗炎症性肠病

Country Status (8)

Country Link
US (2) US20200129534A1 (https=)
EP (1) EP3606535A4 (https=)
JP (3) JP2020513014A (https=)
CN (1) CN110730665A (https=)
AU (2) AU2018250337B2 (https=)
BR (1) BR112019020911A2 (https=)
CA (1) CA3059265A1 (https=)
WO (1) WO2018187792A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111588726A (zh) * 2020-04-28 2020-08-28 南开大学 2′-岩藻糖基乳糖调节宿主肠道菌群及增强肠屏障的应用
CN113486954A (zh) * 2021-07-06 2021-10-08 广西爱生生命科技有限公司 一种肠道微生态差异菌分类处理方法及肠道健康评估方法
CN119842563A (zh) * 2025-03-17 2025-04-18 昆明医科大学第一附属医院(云南省皮肤病医院) 多尔氏菌emf18-06b1d及其用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021111422A1 (en) * 2019-12-06 2021-06-10 Glycom A/S Composition comprising 2'-fl and dfl for use in a method for reducing pain
EP3716984B1 (en) 2017-11-30 2024-03-20 Glycom A/S Mixture of hmos for treating wheat sensitivity
WO2020174386A1 (en) 2019-02-25 2020-09-03 Nutribam Bvba Composition, food supplement and method for supporting and/or improving intestinal health
BE1027078A9 (nl) 2019-02-25 2020-09-28 Nutribam Bvba Samenstelling, voedingssupplement en werkwijze voor het ondersteunen en/of verbeteren van de darmgezondheid
JP2023501111A (ja) * 2019-11-14 2023-01-18 グリコム・アクティーゼルスカブ 腸管における胆汁酸プロファイルを均衡させるための合成組成物
WO2022122721A1 (en) * 2020-12-11 2022-06-16 Dsm Ip Assets B.V. Improved prebiotic formulations
US20260000713A1 (en) * 2021-12-01 2026-01-01 Cedars-Sinai Medical Center Microbial metabolites on intestinal inflammation
US20250213600A1 (en) 2022-03-18 2025-07-03 Meiji Co., Ltd. Composition for controlling growth of bacteria in the intestinal tract and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120202753A1 (en) * 2009-07-06 2012-08-09 Children's Hospital Medical Center D/B/A Cincinnati Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
WO2016066174A1 (en) * 2014-10-29 2016-05-06 Glycom A/S Synthetic composition and method for promoting mucosal healing

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200091B2 (en) * 2010-07-12 2015-12-01 The Regents Of The University Of California Bovine milk oligosaccharides
US20120020941A1 (en) * 2010-07-26 2012-01-26 Suomen Punainen Risti Veripalvelu Use of blood group status iii
WO2012158517A1 (en) * 2011-05-13 2012-11-22 Glycosyn LLC The use of purified 2'-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics
CN104507483A (zh) * 2012-04-13 2015-04-08 波士顿学院理事会 益生元组合物及使用方法
EP2687845A1 (en) * 2012-07-20 2014-01-22 Nestec S.A. Fucose as a biomarker for gut immunity
HK1245658A1 (zh) * 2015-01-23 2018-08-31 Société des Produits Nestlé S.A. 可用於治疗ibd患者的营养组合物
PT3071235T (pt) * 2015-01-26 2018-02-21 Kaleido Biosciences Inc Produtos terapêuticos de glicanos e respetivos métodos relacionados
ES2886951T3 (es) * 2015-09-14 2021-12-21 Glycom As Composición para su uso en la modulación de la microbiota

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120202753A1 (en) * 2009-07-06 2012-08-09 Children's Hospital Medical Center D/B/A Cincinnati Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
WO2016066174A1 (en) * 2014-10-29 2016-05-06 Glycom A/S Synthetic composition and method for promoting mucosal healing

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111588726A (zh) * 2020-04-28 2020-08-28 南开大学 2′-岩藻糖基乳糖调节宿主肠道菌群及增强肠屏障的应用
CN113486954A (zh) * 2021-07-06 2021-10-08 广西爱生生命科技有限公司 一种肠道微生态差异菌分类处理方法及肠道健康评估方法
CN113486954B (zh) * 2021-07-06 2023-04-07 广西爱生生命科技有限公司 一种肠道微生态差异菌分类处理方法及肠道健康评估方法
CN119842563A (zh) * 2025-03-17 2025-04-18 昆明医科大学第一附属医院(云南省皮肤病医院) 多尔氏菌emf18-06b1d及其用途

Also Published As

Publication number Publication date
US20200129534A1 (en) 2020-04-30
AU2024203194A1 (en) 2024-05-30
CA3059265A1 (en) 2018-10-11
US20220133758A1 (en) 2022-05-05
JP2020513014A (ja) 2020-04-30
JP2025041753A (ja) 2025-03-26
AU2018250337A1 (en) 2019-10-24
EP3606535A1 (en) 2020-02-12
BR112019020911A2 (pt) 2020-05-12
EP3606535A4 (en) 2020-12-16
JP2023052629A (ja) 2023-04-11
WO2018187792A1 (en) 2018-10-11
AU2018250337B2 (en) 2024-02-15

Similar Documents

Publication Publication Date Title
US20220133758A1 (en) Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds
Caenepeel et al. how the intestinal microbiota may reflect disease activity and influence therapeutic outcome in inflammatory bowel disease
Turner et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence‐based consensus guidelines
Dolan et al. Diet, gut microbes, and the pathogenesis of inflammatory bowel diseases
Sood et al. Diet and inflammatory bowel disease: The Asian Working Group guidelines
US9386793B2 (en) Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
Macia et al. Microbial influences on epithelial integrity and immune function as a basis for inflammatory diseases
JP2020532515A (ja) マイクロバイオーム関連障害の処置のための方法および組成物
Franzin et al. Microbiota and drug response in inflammatory bowel disease
Rampton et al. Fast Facts: Inflammatory Bowel Disease: Translating the Science Into Compassionate IBD Care
Taguer et al. The complex interplay of diet, xenobiotics, and microbial metabolism in the gut: Implications for clinical outcomes
Melton et al. Mechanisms underlying the effectiveness of exclusive enteral nutrition in Crohn's disease
US20190224230A1 (en) Use of Resistant Potato Starch as a Prebiotic to Modify Microbiota
WO2017000868A1 (zh) 一种组合包在制备用于改善和治疗人类小胖威利综合症的食品、药品、保健品、营养品中的应用
Singh et al. Dysbiosis—an etiological factor for cardiovascular diseases and the therapeutic benefits of gut microflora
O’reilly et al. Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches
Bertin et al. Diet and gut microbiota in inflammatory bowel disease: a clinical and nutritional perspective
Stevenson et al. Probiotic effect and dietary correlations on faecal microbiota profiles in irritable bowel syndrome
US20210268037A1 (en) Anaerostipes hadrus for use in promoting health
Sakiyama et al. Ultra-low-dose lactulose modulates the gut microbiota in healthy adults: A double-blind, randomized, placebo-controlled crossover trial
BR122024023543A2 (pt) Composição farmacêutica, kit e usos de compostos 2'-fucosilactose no tratamento de doenças inflamatórias intestinais
Zhu et al. The changes of gut microbiota and metabolites in different drug-induced liver injuries
Han et al. The utilization of oral feeding in pediatric pancreatitis: a randomized controlled study
Haddadi et al. Signs, symptoms and complications of non-Hodgkin's lymphoma according to grade and stage in south Iran
Blee Assessing the role of dietary interventions on the gut microbiome: a potential therapeutic for IBD

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination